文献速递心律失常血脂与心血管预防

非瓣膜性房颤患者服用新型口服抗凝药的大出血预测新模型

Novel bleeding prediction model in atrial fibrillation patients on new oral anticoagulants.
PubMed 文献 · Heart · 2021-09-21

本研究基于以色列Clalit健康服务数据库,纳入2013-2017年新使用NOAC的房颤患者,开发并验证一个预测大出血的风险评分模型。最终模型包含9个变量,在阿哌沙班组AUC为0.6546,达比加群组c指数0.62,利伐沙班组0.61。结论为模型简单且有一定预测能力,但需外部验证。

要点

  • 新模型含9个预测变量:男性、贫血、血小板减少、联用抗血小板药、高血压、既往大出血、跌倒风险因素、低胆固醇、低eGFR。
  • 模型在阿哌沙班组AUC 0.6546,达比加群组c指数0.62,利伐沙班组0.61。
  • 模型仅基于NOAC使用者开发,需在更多队列中验证。

核心结论

  • 提出一个用于非瓣膜性房颤NOAC治疗患者大出血预测的简易新风险评分,需外部验证。

研究设计与样本

  • 变量筛选采用前向选择(50个bootstrap样本)结合基于改良贝叶斯信息准则的后向选择(竞争风险模型)。

主要发现

  • 最终评分系统含9个变量:男性、贫血、血小板减少(<99×10^3/µL)、联用抗血小板药、高血压、既往大出血、跌倒风险因素、低胆固醇、低eGFR。
  • 阿哌沙班组表观AUC为0.6546。

关键数值与推荐

  • 评分变量包括:男性、贫血、血小板计数<99×10^3/µL、联用抗血小板治疗、高血压、既往大出血、跌倒风险因素、低胆固醇水平、低eGFR。
  • 阿哌沙班组AUC 0.6546,达比加群组c指数0.62,利伐沙班组c指数0.61。

临床怎么用

  • 该评分可用于NOAC治疗的房颤患者大出血风险分层,但预测能力中等,需结合临床判断。
  • 评分变量均为常规可获取的临床指标,便于临床应用。

局限性

  • 模型需在额外队列中验证。
  • 开发阶段仅基于阿哌沙班使用者,外部适用性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Clinical models such as the HAS-BLED (standing for Hypertension, Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile INR, Elderly, Drug/alcohol usage) were developed to predict risk of major bleeding on vitamin K antagonists/antiplatelet therapy. We aimed to develop a model that will improve the ability to predict major bleeding events in patients with non-valvular atrial fibrillation (AF) treated with new oral anticoagulants (NOACs). METHODS: Clalit Health Services is the largest of four integrated healthcare organisations in Israel, which insures 4.7 million patients (53% of the population). We identified in Clalit Health Services all patients with AF, new users of an NOAC (2013-2017), and followed them until first occurrence of a major bleeding event, death, switch to another oral anticoagulant, 30 days after discontinuation of NOAC or end of follow-up (31 December 2019). Importance of the candidate model variables was estimated by inclusion frequencies across forward selection algorithm applied to 50 bootstrap samples. Then, backward selection algorithm using the modified Bayesian Information Criterion for competing risks was applied to select predictors for the final model. RESULTS: 47 623 patients with AF prescribed NOAC were studied. 28 055 patients with AF, initiators of apixaban (mean age 78.7, SD 9.0), were included in the first phase and had 662 major bleeding events. Nine variables were selected for inclusion in a final points-based risk-scoring system: male sex, anaemia, thrombocytopaenia (<99×103/µL), concurrent antiplatelet therapy, hypertension, prior major bleeding, risk factors for a fall, low cholesterol level and low estimated glomerular filtration rate, with apparent area-under-curve (AUC) of 0.6546. Applicability of the model was then shown for 14 118 and 5450 patients with AF, initiators of dabigatran and rivaroxaban, where the score achieved c indices of 0.62 and 0.61, respectively. CONCLUSIONS: We present a novel and simple risk score for prediction of major bleeding in patients with non-valvular AF treated with NOACs. Validation in additional cohorts is warranted.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Barnett-Griness O, Stein N, Kotler A, et al. Novel bleeding prediction model in atrial fibrillation patients on new oral anticoagulants. Heart. 2021. PMID: 34548336. doi:10.1136/heartjnl-2021-319702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。